Published in Proc Natl Acad Sci U S A on August 01, 1982
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A (1985) 2.64
Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A (1987) 0.99
Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A (1995) 0.97
A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. Proc Natl Acad Sci U S A (1992) 0.96
Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci U S A (1995) 0.93
Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype. Am J Pathol (1992) 0.92
Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature (1979) 3.06
Decreased adhesion of platelets to subendothelium in von Willebrand's disease. J Lab Clin Med (1974) 2.44
Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest (1978) 1.49
Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate--dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med (1978) 1.46
Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood (1978) 1.39
Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation. Br J Haematol (1974) 1.29
Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br J Haematol (1980) 1.14
Ultrastructural studies on the platelet plug formation in bleeding time wounds from normal individuals and patients with von Willebrand's disease. Acta Pathol Microbiol Scand Suppl (1974) 1.14
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Plasma levels of platelet aggregating factor/vom Willebrand factor in various species. Thromb Res (1977) 1.01
Von Willebrand's disease. Prog Hemost Thromb (1976) 0.97
Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease. Am J Pathol (1981) 0.85
Platelet-vessel-wall interactions: experiences with von Willebrand platelets. Ann N Y Acad Sci (1981) 0.81
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (1992) 11.83
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med (1999) 4.61
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 3.39
Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem (1997) 3.04
Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A (1997) 2.99
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science (1993) 2.95
PROTHROMBIN DEFICIENCY AND THE BLEEDING TENDENCY IN LIVER INJURY (CHLOROFORM INTOXICATION). J Exp Med (1937) 2.20
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest (1994) 1.98
Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest (2000) 1.84
Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med (1975) 1.82
PROTHROMBIN DEFICIENCY THE CAUSE OF BLEEDING IN BILE FISTULA DOGS. J Exp Med (1936) 1.68
Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A (1989) 1.68
Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol (1999) 1.61
THE USE OF PURIFIED THROMBIN AS AN HEMOSTATIC AGENT. Science (1939) 1.54
Gene therapy and the hemophilias. JAMA (1994) 1.48
Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A (1985) 1.47
Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest (2001) 1.45
Microvillus inclusion disease. In vitro jejunal electrolyte transport. Gastroenterology (1991) 1.44
Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol (1971) 1.39
Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sci U S A (1974) 1.38
Morphologic manifestations of blood-solid interfacial reactions. A scanning and transmission electron microscopic study. Lab Invest (1969) 1.34
The sexual adaptation of women treated for endometrial cancer. Cancer Pract (1994) 1.33
Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci U S A (1990) 1.28
Factor VIII recombination after dissociation by CaCl12. Proc Natl Acad Sci U S A (1973) 1.27
Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand Factors. Proc Natl Acad Sci U S A (1973) 1.27
Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol (1999) 1.23
Thrombocytopenia of hibernation. Mechanism of induction and recovery. Lab Invest (1973) 1.21
Von Willebrand factor: gene dosage relationships and transfusion response in bleeder swine--a new bioassay. Proc Natl Acad Sci U S A (1974) 1.20
Muscular dystrophy in biliary fistula dogs; possible relationship to vitamin E deficiency. Am J Pathol (1941) 1.18
Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb (1993) 1.17
Expression and linkage of genes for X-linked hemophilias A and B in the dog. Blood (1973) 1.17
Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther (1996) 1.12
Parathyroid hyperplasia and parathyromatosis. Lancet (1977) 1.10
The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood (1993) 1.10
Papillary cystic neoplasm of the pancreas: a curable pancreatic tumor. World J Surg (1986) 1.09
Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci U S A (1978) 1.04
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA (1976) 1.03
The role of noninvasive tests versus pulmonary angiography in the diagnosis of pulmonary embolism. Am J Med (1981) 1.02
Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood (1989) 1.02
Venom coagglutinin for detection of von Willebrand factor activity in animal plasmas. J Lab Clin Med (1983) 1.02
Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays. Thromb Res (1978) 1.02
HEPARIN AND THE ANTITHROMBIC ACTIVITY OF PLASMA. Science (1942) 1.01
Is physical activity or aerobic power more influential on reducing cardiovascular disease risk factors? Med Sci Sports Exerc (1998) 1.01
Antibody to a soluble acidic nuclear antigen in Sjögren's syndrome. Am J Med (1977) 1.01
Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg (1992) 1.01
Plasma levels of platelet aggregating factor/vom Willebrand factor in various species. Thromb Res (1977) 1.01
Salivary gland anlage tumor ("congenital pleomorphic adenoma"). A clinicopathologic, immunohistochemical and ultrastructural study of nine cases. Am J Surg Pathol (1994) 1.00
Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A (1987) 0.99
Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med (2000) 0.99
The platelet: membrane and surface reactions. Annu Rev Physiol (1976) 0.98
Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A (1995) 0.97
Hemangiopericytoma: a light microscopic and ultrastructural study. Cancer (1981) 0.97
Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test. Thromb Res (1975) 0.97
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest (1997) 0.96
von Willebrand's disease prevents occlusive thrombosis in stenosed and injured porcine coronary arteries. Circ Res (1986) 0.95
Osteogenic sarcoma: a study of the ultrastructure. Cancer (1980) 0.95
Platelet agglutination and deagglutination with a sulfhydryl inhibitor, methyl mercuric nitrate: relationships to platelet ATPase. Exp Mol Pathol (1965) 0.95
The myofibroblast. Pathol Annu (1980) 0.95
Case reports and medical progress. Perspect Biol Med (1985) 0.94
Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest (1997) 0.94
Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor. Blood (1980) 0.93
A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA (1968) 0.93
Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci U S A (1995) 0.93
Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype. Am J Pathol (1992) 0.92
Scanning electron microscopy of synovial membranes. Arch Pathol (1972) 0.92
Cadaver lung donors: effect of preharvest ventilation on graft function. Ann Thorac Surg (1993) 0.92
Fibrinogen--its role in platelet agglutination and agglutinate stability. A study of congenital aibrinogenemia. Lab Invest (1966) 0.91
Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model. Lab Invest (1988) 0.91
Beta-adrenergic blocking agents after myocardial infarction: an undocumented need in patients at lowest risk. J Am Coll Cardiol (1983) 0.90
Freeze-etch observations on the plasma membrane and other structures of normal and abnormal platelets. Am J Pathol (1973) 0.89
Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc Natl Acad Sci U S A (1975) 0.89
Fresh water drowning. Pulmonary ultrastructure and systemic fibrinolysis. Arch Pathol (1974) 0.88
Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci (1965) 0.88
Cutaneous infarction. Manifestation of disseminated mucormycosis. Arch Dermatol (1977) 0.87
Autonomously functioning thyroid nodules in childhood and adolescence. Surgery (1987) 0.87
Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. Proc Natl Acad Sci U S A (1983) 0.87
Malignant soft tissue tumors (malignant fibrous histiocytoma, pleomorphic liposarcoma, and pleomorphic rhabdomyosarcoma): an electron microscopic study. Hum Pathol (1979) 0.87
Epithelioid leiomyosarcoma of the small intestine with oncocytic change. Arch Pathol Lab Med (1987) 0.86
Angiosarcoma of the uterus: a light microscopic, immunohistochemical, and ultrastructural study. Int J Gynecol Pathol (1987) 0.86
In situ and infiltrating lobular carcinoma of the male breast. Hum Pathol (1989) 0.86
Characterization of human platelets separated from blood by ADP-induced aggregation. Am J Pathol (1975) 0.86
Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion. Proc Natl Acad Sci U S A (1977) 0.86